Objective To understand the status and influencing factors of job burnout in medical staff providing highly active antiretroviral therapy(HAART)for people living with human immunodeficiency virus(HIV)in Yunnan province.Methods Using cluster sampling method,the self-made general information questionnaire and Chinese version of Maslach burnout inventory(CMBI)were published in Yunnan province HAART information management system in January 2022 for investigation.Results A total of 442 valid questionnaires were received.The detection rate of job burnout was 53.39%,emotional exhaustion was 15.61%,depersonalization was 21.04%,and reduced personal accomplishment was 38.01%.Binary Logistic regression analysis showed that the medical staff with high frequency of working overtime(OR=2.793,95%CI:1.844-4.213)and low equity of pay(OR=0.676,95%CI:0.496-0.921)were more prone to emotional exhaustion.The medical staff with low equity of pay(OR=0.705,95%CI:0.547-0.908)were more prone to depersonalization.The medical staff with low frequency of working overtime(OR=0.749,95%CI:0.572-0.981)and work in primary HAART sites(tertiary OR=0.377,95%CI:0.161-0.883,secondary OR=0.438,95%CI:0.242-0.794)were more prone to low personal accomplishments.Conclusion The status of job burnout among medical staff providing HAART for people living with HIV in Yunnan province is at middle level and has a significant reduction of personal accomplishments.It is suggested to alleviate the burnout of medical staff through improving workflow of HAART,planning reasonable rewarding system,valuing the physical and mental health of primary medical staff.

Objective To investigate the applicability of beliefs about medicines questionnaire specific(BMQ-specific)in HIV/AIDS patients receiving highly active antiretroviral therapy(HAART).Methods From November to December in 2021,583 HIV/AIDS patients receiving HAART in 3 clinical treatment sites were selected according to the prevalence of HIV/AIDS in Yunnan Province by matched sampling.The applicability evaluation of the scale includes item analysis,validity and reliability test.Results BMQ-specific had good discrimination(P＜0.001),and the correlations between score of each item and the respective dimension total score ranged from 0.641-0.820(P＜0.001).The results of exploratory factor analysis and validation confirmatory factor analysis showed that the model fitting indicators were within the standard range.The item-content validity index of each item was beyond 0.78,and the scale-content validity index was 0.970.BMQ-specific scores were significantly correlated with the Morisky medication adherence scale 8-item version(P＜0.001).Reliability analysis showed that the Cronbach's α of necessity and concern were 0.854 and 0.790 respectively,and the corrected item-total correlation values of 10 items were larger than 0.5,if item deleted was all smaller than the Cronbach's α in the corresponding dimensions,the test-retest reliability of the two dimensions with for-week interval was 0.786 and 0.753.Conclusion The Chinese version of BMQ-specific had proved its good applicability in HIV/AIDS patients receiving HAART.

Objective:To investigate the efficacy and safety of promestriene vaginal gelatin capsules administered through different schemes in the treatment of postmenopausal female urethral syndrome.Methods:A total of 120 patients with postmenopausal female urethral syndrome who received treatment in General Hospital of Medical and Health Group of Cixi Third People's Hospital from January 2021 to June 2022 were included in this study. They were randomly divided into groups A and B ( n = 60/group). Group A was treated with vaginal gelatin capsules containing 10 mg promestriene once a day. Group B was treated with vaginal gelatin capsules containing 10 mg promestriene twice a day. Both groups were treated for 20 days as a course of treatment. The improvement of symptoms, lower urinary tract symptom score, quality of life score, estradiol level, follicle stimulating hormone level, and endometrial thickness were compared between the two groups. Results:After treatment, the scores of incomplete urination, urination interval, intermittent urination, dysuria, thinner urine line, urination force, and nocturnal urination times in group A were (2.51 ± 1.76) points, (2.66 ± 1.08) points, (2.61 ± 1.45) points, (2.48 ± 1.42) points, (2.85 ± 1.03) points, (2.48 ± 1.42) points, and (2.52 ± 1.72) points, respectively, which were significantly lower than (3.15 ± 1.35) points, (3.23 ± 1.14) points, (2.99 ± 1.57) points, (3.08 ± 1.09) points, (3.45 ± 1.72) points, (3.25 ± 1.08) points, and (3.21 ± 1.87) points, respectively, in group B ( t = 10.57, 9.78, 13.83, 10.34, 9.35, 12.34, 9.45, all P < 0.05). The quality of life score in group A was (2.45 ± 0.86) points, which was significantly lower than (3.51 ± 0.92) points in group B ( t = 5.45, P < 0.05). There were no significant differences in estradiol and follicle stimulating hormone levels and endometrial thickness between the two groups before and after treatment (all P > 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion:Local application of promestriene vaginal gelatin capsules can improve the urethral syndrome in postmenopausal women. The once daily 10 mg promestriene vaginal gelatin capsule administration scheme can achieve better efficacy and safety than the twice daily administration scheme. The study is innovative, scientific, and worthy of clinical promotion.